Sign in
4

Changes in Ownership

ENANTA PHARMACEUTICALS INC Filed Acc 0001062993-24-012734

Chief Product Strategy Officer sold 7,266 shares at $12.33 ($89,590)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kieffer Tara Lynn Chief Product Strategy Officer 2024-06-17 Sale 10b5-1 −7,266 $12.33 $89,590 32,341 D
Open-market sales · 7,266 sh · avg $12.33 · $89,590
Loading xslF345X05/form4.xml…